drugset / Trial / NCT04916769

Bioavailability of Bosutinib Administered as Capsule Contents Mixed With Applesauce or Yogurt Relative to Intact Capsules Under Fed Condition

NCT04916769

Phase 1 Completed 18 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

This study is intended to estimate the relative bioavailability of a single 500 mg dose of bosutinib when administered as capsule contents mixed with applesauce or yogurt to intact capsules under fed condition in adult healthy participants. The comparisons will be performed using the pharmacokinetic parameters that define the rate and extent of absorption, those are Cmax and AUC. Statistical analyses will be performed comparing these parameters calculated after administration of a single 500 mg dose with the intact capsule formulation (100 mg x 5) as the Reference treatment and the capsule contents mixed with applesauce or yogurt (100 mg x 5) as the Test treatments.

Timeline

Start
2021-08-13
Primary completion
2022-01-27
Completion
2022-01-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bosutinib Small molecule 500 mg

Indications

No indication recorded.